Filed by Cellebrite DI Ltd.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934
Subject Company: TWC Tech Holdings II Corp.
Commission File No. 001-39499
Date: August 12, 2021



# Q2 21 Earnings Call

June 2021



### Disclaimer

This presentation ("Presentation") contains progrietary and confidential information of Celebrite DLUL, ("Celebrite" or the "Company") and TWC Tech Holdings II Corp. ("TWC") and the entire contents should be considered "Confidential Information." This Presentation is made solely for informational purposes, and no representation or warranty, express or implied, is made by Celebritis, TWC or any of their representatives as to the information contained in these materials or disclosed during any related presentations or discussions. The recipient of this Presentation and its contents confidential, shall not use this Presentation for any purpose of data by a complete of the Celebritis or its contents for any purpose or other than as expressly adult of the required to return or destroyal copies of this Presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this Presentation, the recipient is deemed to agree to the foregoing confidentiality requirements.

This Presentation is for informational purposes and does not constitute an offer to sell, a solicitation of an effer to buy, or a recommendation to purchase any equity, debt or other financial instruments of Celebrite, TWC or any of their respective affiliates. The information contained herein does not purpor to be all-inclusive. No representations or warranties, expense or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will Celebrite, TWC or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, derectors, offerent, employees, investment banks, advasors or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, relance on the information contained within R, or on opinions communicated in relation thereto or otherwise arising in connection therewise.

Industry and market data used in this Presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither Celebritie nor TWC has independently verified the data obtained from these sources and cannot assure you of the data's occuracy or completeness. No representation is made as so the reasonableness of the assumptions made within or the accuracy or completeness or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. TWC and Celebritie assume on obligations to update any information in this Presentations, except as required by law.

Important Information About the Business Combination and Where to Find It In connection with the proposed business combination between Celebrite and TWC, Celebrite has filed a registration statement on Form F-4 that includes a proxy statement of TWC in connection with TWC's solicitation of proxies for the vote by its stockholders with respect to the proposed business combination and other matters as may be described in the registration statement. The registration statement on Form F-4 was declared effective on August 6, 2021. Cellabrite and TWC also plan to file other documents with the Securities and Schange Commission (the "SCF" regarding the proposed transaction and a proxy statement / prospects as labo being malled to TWC's stockholders. Before making any investment or voting decision, stockholders and other interested persons are advised to read the registration statement and proxy statement / prospects regarding the proposed transaction and any other relevant documents, including any amendments or supplements to these documents, carefully and in their entirety because these materials will contain important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite, TWC and the proposed transaction and any other important information about Cellabrite and TWC are available, without charge, at the SEC's website at www.sec.equilibrite. prospectus, as well as other file 2100, San Francisco, CA 94111.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CHIMINAL OFFENSE.

Participants in the Solicitation
Cellabritie and TWC and certain of their respective directors, executive officers and members of management may, under SEC rules, be deemed participants in the solicitation of proxies of TWC stockholders in connection with the proposed business combination. TWC stockholders, Cellabritie's shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Cellabritie and TWC at Cellabritie's website at www.cellabrita.com, or in the proxy statement/proposcitus on Form F-4 filed by Cellabritie with the SEC.

sation regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to TWC's stockholders in connection with the proposed transaction may be obtained by reading the proxy statement / prospectus for the proposed transaction. Additionation regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction may be obtained by reading the proxy statement / prospectus for the proposed transaction.

No Offler or Solicitation
This Presentation does not constitute a solicitation of a grow, consent or authorization with respect to any securities or in respect of the business combination. This Presentation also does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of securities and state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of Securities Act of 1933, as amended, or an exemption therefore.

Industry and Market Data
This Presentation includes information and statistics regarding market participants in the sectors in which Cellebrite competes and other industry data which was obtained from third-party sources, including reports by market research firms and company filings.

This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM © or \* symbols, but TWC and Cellebrite will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.



## Disclaimer

### Use of Non-GAAP Financial Measures

Use or Non-GAAP Financial measures in addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this Presentation includes non-GAAP financial measures, non-GAAP operating income and Adjusted EBITDA. These non-GAAP measures have limitations as analytical tools, and they should not be considered in location from, or as an alternative to, in aniernative to, in financial measures determined in accordance with GAAP. Other companies may calculate these non-GAAP financial measures of other companies, in a differently, and therefore such financial measures way not be directly companable to similarly titled measures of other companies, in addition, such information and data may not be included in, may be adjusted in or may be presented differently and information and data may not be included in, may be adjusted in or may be presented differently and information and data may not be included in any proxy statement or registration statement to be filed by Cellebrite or TWC with the SEC. A reconciliation of certain of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this

Projections
This Presentation contains projected financial information with respect to Cellebrite. Such projected financial information constitutes forward-looking information, is for illustrative purposes only and should not be relied upon as necessarily indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the projected financial information. See "Forward looking Statements" paragraph below. Actual results may differ materially from the results contemplated by the projected financial information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such projections will be achieved. Neither the independent auditors of TWC nor the independent registered public accounting firm of Cellebrite audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and, accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation.

Forward Looking Naterments
This Presentation also contains forward-looking statements, which may be identified by such words as "may,", "should", "would", "plain", "intend", "expect", "believe", "anticipate", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "lifture", "utilized", "outlook", or other similar expressions, words or phrases, or by their context. These statements include statements regarding the industry in which the combined companies will operate, future events, the proposed transactions of the parties of the parties to successfully consummate the proposed transaction, future opportunities for the combined company, and other statements that are not historical facts. These statements are made on the basis of current knowledge and current expectations of TWC and Celebrite management and, by their antarity, involved. merous assumptions and uncertainties and are not predictions of actual performance. Nothing set forth herein should be regarded as a representation, warranty, or prediction that TWC or Cellebrite will achieve or are likely to achieve any particular future result.

In addition to the factors previously disclosed in Cellebrite's reports filed with the SEC and those identified elsewhere in this Presentation, the following factors, among others, could cause results to differ materially from the forward-looking statements in this release or historical performance: (1) risks and uncertainties related to the inability of the parties to successfully or timely consummate the Business Combination, including the risk that any required regulatory approvals or stockholders; (3) the ability to meet Nasday's Island gardands for the standards of any other securities of the public natity are lated following the consummation of the Business Combination; the inability to complete the private placement of ordinary shares of Cellebrite to certain institutional accredited investors; (4) the risk that the proposed transaction disrupts current plans and operations of Cellebrite as a result of the announcement and consummation of the transactions described herein; (5) the ability to recognize the annitipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and relatin its management also were expected intentions of COVID-19; (6) costs related to the proposed Business Combination; the outcome of any legal proceedings that may be instituted against Cellebrite. TWC, or any of their respective directors or officers, regarding the proposed transaction; (7) the ability of Cellebrite or the combined company to issue equity or equity-linked securities in connection with the proposed business combination or in the future; the failure to realize articipated pro formar exists and underlying assumptions, including with respect to estimated stockholder redemptions and purchase price and other adjustments; (8) changes in applicable laws or regulations; (9) the possibility that Cellebrite may be adversely affected by other economi contained in the amended registration statement on Form F-4 relating to the business combination filed by Cellebrite originally on May 17, 2021, as amended.



# Investment highlights



Cellebrite is the clear market leader with 99% win rate within digital intelligence

Massive \$12B+ market opportunity for digital intelligence ("DI") solutions with major secular tailwinds supporting continued growth

Unique mission critical end-to-end digital intelligence platform that serves the world's leading government agencies and enterprises at each stage of the investigative lifecycle

Rapidly growing Enterprise opportunity with segment revenue projected to double by 2023

Fragmented landscape of point solutions with numerous actionable targets and significant resources to support execution of highly strategic M&A thesis

World class, mission driven management team with deep industry expertise

Compelling financial profile with 46% ARR growth and 142% ARR net retention in LTM June 2021



## Cellebrite empowers the world's leading government agencies and enterprises



### **Federal**

100+ North American Federal Accounts

14 of 15 U.S Cabinet **Executive Departments** 



25 of 27 member E.U. National Police



### State & Local

2,700+ North American State and Local Accounts

50 of 50 U.S. States

Police Departments at 20 of Largest 20 U.S. Cities

Police Departments at 11 of Largest 20 Cities Globally



### **Enterprise**

9 of Top 10 Accounting Firms

6 of Top 10 Pharma Companies

8 of Top 10 U.S. Commercial Banks

5 of Top 10 Auto Manufacturers

6 of Top 10 **Petroleum Refiners** 

6 of Top 10 Telecom companies

9 of Top 10 U.S. **Software Companies** 





## Q2 21 customer successes

### **Customer Traction**

- Increasing number of large multi-solution deals
  - 1 customer >\$5M
  - → 9 customers >\$1M

## **Large Deal Example 1**

- Scandinavian long-term customer
- Need: improve efficiency and reduce backlogs
- + Pre-booking of Premium Enterprise
  - + >100 UFEDs

## **Large Deal Example 2**


- N. American District Attorney
- Need: new legislation requiring faster evidence submitting
- Premium Collect & Review, Analytics

## **Large Deal Example 3**

- Private sector digital forensics and analytics service provider
- Need: geographic expansion
- Collect & Review, Management
- Largest private sector deal ever



# Cellebrite delivers a comprehensive DI software platform



Empowering Chiefs of Investigations & Intelligence with end-to-end investigative platform



# Cellebrite Premium Enterprise







## Cellebrite Pathfinder 8.6









## Professional services enhancement



- System Integration, Automation and Customization
- Advisory and Consulting
- Business Discovery



- ♦ Advanced Digital Data Access and Collection
- Crypto Investigations
- Expert Lab Services



- + DI Training
- Customized Training
- Certification and Accreditation
- Mentorship Program






- + Remote Global Support
- + On-site Health Checks
- Custom Webinars and Expert Hours



# Significant near-term growth opportunity



<sup>&</sup>lt;sup>1</sup> Source: The State of E Discovery Guide 2020 by Exterro and ACEDS.



## Transaction timing and certainty

Business combination expected to close in Q3 2021 with significant deal certainty given that minimum cash requirement has predominately been fulfilled through the \$300M of PIPE agreements already in place

**Diligence & Documentation** 

Shareholder Vote & Deal Close



April 8th, 2021 Deal Announcement & Signed Business Combination Agreement



May 17th, 2021 Cellebrite Files Preliminary F-4 with the Securities & Exchange Commission



June 7th, 2021 Cellebrite Announces Q1'21 **Financial Results** Highlighting Continued Strength and Trajectory




August 6th, 2021 Registration Statement Effectiveness



August 27th, 2021 Shareholder Vote to Approve Transaction







# Financial highlights



Sustainable ARR Growth

**46%**ARR Growth
Q2 '21



Best-in-class
Retention metrics

142%

Net Retention LTM Jun-21

98%

Gross Retention 2020



Strong Margin profile

**83**%

Gross Margin LTM Jun-21


**22**%

Adj. EBITDA Margin LTM Jun-21

Note: non-GAAP metrics and key performance indicators defined in the appendix.



# Sustainable ARR growth



 $<sup>^{\</sup>rm 1}\,\mbox{Growth}$  rates compare to ARR from the same quarter end in the prior year.





# ARR growth driven by expansion





# Revenue growth driven by subscription








## Profitability expansion


## Gross profit (\$M) and margin



## **Expected H2 21 Opex Increase**

- + Travel
- Field marketing events
- → Hiring ~80 employees

## Operating expenses (Non-GAAP, \$M) and % of sales1



## Adj. EBITDA (\$M) and margin





 $<sup>^{\</sup>rm 1}$  Non-GAAP operating expenses exclude one-time expenses, share-based compensation, amortization of intangible assets, and acquisition related expenses.


# Financial outlook

Strong operational metrics

	2021E	2022E
ARR Growth	44%	32%
Revenue Growth	21%	20%
Adjusted EBITDA Margin	15%	18%

Ľ	Long Term	j
Г   	22 – 27%	
i I	20 – 24%	
	25 – 35%	į





# Financial summary – Q2

(\$K)	June 20A	June 21A
ARR	109,153	158,895
YOY Growth - %	36%	46%
Subscriptions	31,168	41,458
Perpetual License & Others	10,506	10,382
Professional Services	4,096	7,328
Total Revenue	45,770	59,168
YOY Growth - % <sup>2</sup>	22%	29%
Gross Profit	37,551	49,100
Gross Profit - %	82.0%	83.0%
Adjusted EBITDA	8,443	13,379
Non-GAAP EBITDA - %	18.4%	22.6%

# Financial summary - annual

(\$K)	2019A	2020A	2021E	2022E
ARR	91,910	137,050	197,274	260,826
YOY Growth - %	28.4%	49.1%	43.9%	32.2%
Subscriptions	86,647	129,745	180,876	228,500
Perpetual License & Others	59,175	42,136	26,538	20,484
Professional Services	26,032	23,032	28,223	33,816
Total Revenue	171,854	194,913	235,637	282,800
YOY Growth - %	14.8%	13.4%	20.9%	20.0%
Gross Profit	136,031	157,034	190,827	228,293
Gross Profit - %	79.2%	80.6%	81.0%	80.7%
Adj. EBITDA	19,352	31,117	36,463	50,653
Adj EBITDA - %	11.3%	16.0%	15.5%	17.9%



# Operating income reconciliation – Q2

(\$K)	June 20A	June 21A
Operating Income in Financial Statements	1,665	8,221
One time expense (Former co-founder compensation)	1,519	-
Share Based Compensation Expense	2,127	2,363
Amortization of Intangible Assets	387	435
Acquisition Related Costs	1,626	1,096
Non-GAAP Operating Income	7,324	12,115
Non-GAAP Operating Income - %	16.0%	20.5%

# Operating expenses reconciliation – Q2

(\$K)	June 20A	June 21A	
Operating Expenses	35,886	40,879	
Less: One time expense (Former co-founder compensation)	1,519	-	
Less: Share Based Compensation Expenses	2,127	2,363	
Less: Amortization of Intangible Assets	387	435	
Less: Acquisition Related Costs	1,626	1,096	
Non-GAAP Operating Expenses	30,227	36,985	
Non-GAAP Operating Expenses - %	66.0%	62.5%	

# Adjusted EBITDA reconciliation – Q2

(\$K)	June 20A	June 21A
Net Income in Financial Statements	1,963	7,796
Financial Income	(1,015)	(496)
Tax Expenses	717	921
Depreciation & Amortization	1,506	1,699
One-time Expense (Former co-founder compensation)	1,519	
Share Based Compensation Expenses	2,127	2,363
Acquisition Related Costs	1,626	1,096
Adjusted EBITDA	8,443	13,379
Adj EBITDA - %	18.4%	22.6%

# Adjusted EBITDA reconciliation - annual

(\$K)	2019A	2020A	2021E	2022E
Net Income (Loss) in Financial Statements	(1,876)	5,781	14,017	30,096
Financial Income	(2,935)	(2,179)	(1,920)	(2,400)
Tax Expense	3,291	5,616	4,426	9,504
Depreciation & Amortization	4,079	5,879	6,848	6,848
One-time Expense (Former co-founder compensation)	4,034	1,519	-	-
Share Based Compensation Expense	12,759	7,271	5,811	5,903
Acquisition Related Costs		6,542	7,281	702
Capital Loss from FA Disposal		689	_	-
Adjusted EBITDA	19,352	31,118	36,463	50,653
Adj EBITDA - %	11.3%	16.0%	15.5%	17.9%

## **Definitions**

- Annual Recurring Revenue: Annual recurring revenue ("ARR") is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12.
- Subscription Revenue: Is defined as revenue from recurring, term-based license contracts and ongoing services related
  to core offerings. Subscription revenue is recognized ratably over the subscription term with a portion of revenue,
  related to the term-based license, recognized upfront.
- 3. Net Retention: Dollar-based net retention rate is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.

